US EditionSNS812, an innovative siRNA drug from Oneness and Microbio (Shanghai), selected for ATS 2025 oral presentation, demonstrating world-leading clinical outcomes in COVID-19 treatment
Summary by Aspen Daily News
3 Articles
3 Articles
All
Left
Center
2
Right
Aspen Daily News+2 Reposted by 2 other sources
SNS812, an innovative siRNA drug from Oneness and Microbio (Shanghai), selected for ATS 2025 oral presentation, demonstrating world-leading clinical outcomes in COVID-19 treatment
TAIPEI, May 16, 2025 /PRNewswire/ -- The broad-spectrum antiviral siRNA drug SNS812, co-developed by Oneness Biotech (4743.TW) and Microbio (Shanghai), has been selected for oral presentation at the prestigious 2025 American Thoracic Society (ATS) International Conference. The presentation will deliver…
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
